Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trialAlbert M. Maguire, Jean Bennett, Jessica I. W. Morgan et al.|The Lancet|2009Cited by 857
Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector AdministrationFrancesca Simonelli, Alberto Auricchio, Albert M. Maguire et al.|Molecular Therapy|2009Cited by 551
Mutation of a nuclear receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal cell fateNeena B. Haider, Val C. Sheffield, Samuel G. Jacobson et al.|Nature Genetics|2000Cited by 506
AAV2 Gene Therapy Readministration in Three Adults with Congenital BlindnessJean Bennett, Albert M. Maguire, Manzar Ashtari et al.|Science Translational Medicine|2012Cited by 390
AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized ModelsVidyullatha Vasireddy, Jean Bennett|PLoS ONE|2013Cited by 78